SEARCH

SEARCH BY CITATION

References

  • 1
    Hepatitis B Fact Sheet. World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/index.html (accessed 17 September 2007).
  • 2
    Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. N Engl J Med 2004; 350: 111829.
  • 3
    Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005; 352: 27436.
  • 4
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 67886.
  • 5
    Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 6
    Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S17381.
  • 7
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology 2001; 120: 182853.
  • 8
    Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 4758.
  • 9
    Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133: 14527.
  • 10
    Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 93662.
  • 11
    Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26: 13041.
  • 12
    Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 61724.
  • 13
    Hadziyannis S. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 736.
  • 14
    Chu CJ, Keeffe EB, Han SH, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38: 61928.
  • 15
    Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 2001; 8: 31121.
  • 16
    Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 140815.
  • 17
    Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 1219.
  • 18
    Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR 2006; 55(RR16): 125.
  • 19
    Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 152131.
  • 20
    Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328: 983.
  • 21
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 50739.
  • 22
    Di Bisceglie A, Lai C, Gaines E, More A, Authors M. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients [abstract]. Hepatology 2006; 44: 230A1A.
  • 23
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 268295.
  • 24
    Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 120617.
  • 25
    Marcellin P, Piratvisuth T, Brunetto M, et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) with or without lamivudine: results of 4-year follow-up [abstract]. J Hepatol 2008; 48: S46.
  • 26
    Perrillo RP. Therapy of hepatitis B – viral suppression or eradication? Hepatology 2006; 43: S18293.
  • 27
    Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 141927.
  • 28
    Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 2927.
  • 29
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 80816.
  • 30
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 8007.
  • 31
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B up to 5 years. Gastroenterology 2006; 131: 174351.
  • 32
    Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 100110.
  • 33
    Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 101120.
  • 34
    Shouval D, Akarca U, Hatzis G. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg-chronic hepatitis B patients (study ETV-027) [abstract]. J Hepatol 2006; 130: S212.
  • 35
    Tenny DJ, Pokornowsky KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance [abstract]. Hepatol Int 2008; 2: A889.
  • 36
    Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 257688.
  • 37
    Lai CL, Gane E, Hsu C, et al. Two-year results from GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine [abstract]. Hepatology 2006; 44: 222A.
  • 38
    Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 52836.
  • 39
    Bzowej N, Chan H, Lai C, et al. A randomized trial of telbivudine (LdT) vs. adefovir for HBeAg-positive chronic hepatitis B: final week 52 results [abstract]. Hepatology 2006; 44: 563A.
  • 40
    Heathcote EJ, Ed Gane E, DeMan R, et al. A randomized, double-blind, comparision of tenofovir df (TDF) versus Adefovi dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103 [abstract]. Hepatology 2007; 46: 861A.
  • 41
    Heathcote J, George J, Gordon S, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103) [abstract]. J Hepatol 2008; 48: S32.
  • 42
    Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparision of tenofovir DF (TDF) versus adefovir dpivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-012 [abstract]. Hepatology 2007; 46: 80A.
  • 43
    Marcellin P, Jacobson I, Habersetzer F, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102) [abstract]. J Hepatol 2008; 48: S26.
  • 44
    Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006; 166: 4956.
  • 45
    Shiffman M, Ng T, Krastev Z. A double-blind, placebo controlled trial of emtricitabine (FTC, Emtriva) administered once daily for the treatment of chronic hepatitis B virus (HBV) infection [abstract]. Hepatology 2004; 40: 172A.
  • 46
    Lok AS, Zoulin F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 25465.
  • 47
    Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008; 6: 26874.
  • 48
    Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 14149.
  • 49
    Peters MG, Hann HwH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 50
    Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 30713.
  • 51
    Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 203949.
  • 52
    Van Bömmel F, De Man RA, Stein K, et al. A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience [abstract]. J Hepatol 2008; 48: S32.
  • 53
    Piccolo P, Lenci I, Di Paolo D, et al. Peginterferon-alpha-2a plus adefovir vs peginterferon alpha-2a for 48 weeks in HBeAg-negative chronic hepatitis B: preliminary 24 week results of the PEG FOR B randomized multicenter trial [abstract]. J Hepatol 2007; 46: S26.
  • 54
    Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 8907.